People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food. This is how the drugs work.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion ...
GlobalData on MSN1d
Zealand and Roche strike $5.3bn obesity treatment dealThe two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback